Based in the Nice Côte d’Azur Metropolis, Virbac is a major player in the field of animal health.
The company recently celebrated its 30th anniversary of presence in the Asia-Pacific region, as well as 40 years of operations in Spain, and has announced several strategic developments for 2023. Among the strategic developments announced for 2023 are the creation of a subsidiary in Ireland, the acquisition of its distributor in the Czech Republic and Slovakia, and the appointment of André Mathieu and Manuela Rodriguez to leadership positions within the company.
Virbac will strengthen its presence in India
In line with its expansion strategy, Virbac recently announced the signing of an agreement for the acquisition of Globion, an Indian company specializing in poultry vaccines. This transaction is part of Virbac’s long-term strategy aimed at consolidating its position in the rapidly growing Indian animal health market.
Founded in 2005, Globion is the result of a joint venture between Suguna Group, one of the leaders in the poultry industry in India, and Lohmann Animal Health, a German company specializing in poultry vaccines. With an annual turnover of approximately 12 million euros, Globion employs nearly 120 people in its research and development and production facilities in Hyderabad.
Sébastien Huron, CEO of Virbac, specified “We are extremely pleased and honored to welcome the Globion team into our Virbac family. This acquisition illustrates Virbac’s 2030 vision and its ambition to grow through ‘programmatic’ acquisitions by investing in vaccines, a key strategic axis of development, by strengthening our leadership position in India, the most populous country in the world, and by complementing our portfolio targeting the dynamic and promising poultry market. We will fully commit to the Globion teams and provide them with additional resources to help them give their best. With the teams from Suguna and Globion, we are united by the common ambition to create long-term value for our customers and to build, through innovation, a competitive product portfolio to support the poultry industry in India and abroad.”
B. Soundararajan, founder and CEO of Suguna Group: “We primarily established Globion as a source of high-quality and affordable poultry vaccines for Suguna Foods. Over the past ten years, Globion has rapidly transformed into a fast-growing poultry biological products company, with revenues exceeding one billion rupees, consistently gaining market share in India and in export markets. By partnering with a strategic partner that has a long-term vision, infrastructure, and deep understanding of animal health in both Indian and global markets, we see immense potential for Globion to reach even greater heights. Virbac is the right choice for us because both this company and Suguna share the same vision of creating value for the poultry industry. The acquisition of Globion by Virbac is a significant step in this direction. We will continue to be a key customer of Globion/Virbac in the future, and we wish both the Globion/Virbac teams enduring success.”
Veda Corporate Advisors advised Suguna and Globion in this transaction.
Healthtech / Biotech – Nice Côte d’Azur France
- Nice University Hospital: New Recognition for its Excellence in Research and Innovation
- ExAdEx-Innov and EXSYMOL Monaco: A Collaboration at the Heart of Cosmetic Innovation
- Virbac will enhance its presence in the Indian animal health market
- University of Côte d’Azur and CHU of Nice at the forefront of research on healthy aging
- Nice Côte d’Azur Metropolis Acceleration Program: 12 winning companies.
- Virbac celebrates 30 years in the Asia-Pacific region and announces its consolidated revenue for Q2 2023
- Business Landing Nice Côte d’Azur: Support for business set up in France
- Nice: Caranx Medical Laboratories are one of the winners of the i-Nov Innovation Contest.
- Entrepreneurship in Research Prize 2023
- Venture Capital in France: EY publishes the results for the first half of 2023